Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 2
Submit an article Journal homepage
15
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Maintenance with Pamidronate Following First-line MP or VAD Therapy in Multiple Myeloma

Haruki Kondo Department of Medicine, Division of Haematology and Oncology, Shimizu Kohsei Hospital, 578-1 Ihara-cho, Shimizu-city, Shizuoka 424-0114, Japan
,
Akinori Mori Department of Medicine, Division of Haematology and Oncology, Shimizu Kohsei Hospital, 578-1 Ihara-cho, Shimizu-city, Shizuoka 424-0114, Japan
&
Michio Kubota Department of Medicine, Division of Haematology and Oncology, Shimizu Kohsei Hospital, 578-1 Ihara-cho, Shimizu-city, Shizuoka 424-0114, Japan
Pages 303-307 | Published online: 01 Jul 2009

  • Berenson, J.R. Lichtenstein, A., Porter, L., Dimpoulos, M.A., Bordoni, R., George, S., Lipton, A., Kelter, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J.F., Heffersan, M., Seaman, J. and Knight, R.D. for the Myeloma Aredia Study Group (1998) "Long-term pamidronate treatment of advanced multiple myeloma tatients reducdes skeleral events", Journal of Clinical Oncology 16, 593-602.
  • Abildgaard, N., Rungby, J., Glerup, H., Brixen, K., Kassem, M., Brincer, H., Heickendorff, L., Eriksen, E.F. and Nielsen (1998) "Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple meyloma", European Journal of Haematology 61, 128-134.
  • Dhodapkar, M.V., Weinstein, R., Tricot, G., Jagannath, S., Parfitt, A.M., Manolagas, S.C. and Barlogie, B. (1998) "Biologic and therapeutic determinants of bone mineral density in multiple myeloma", Leukemia and Lymphoma 32, 121-127.
  • Shipman, C.M., Rogers, M.J., Apperley, J.F., Russel, G.G. and Croucher, P.I. (1998) "Bisphosphnates induce apoptosis in human myeloma cell lines: a novel anti-tumor acitvity". British Journal of Haematology 98, 665-672.
  • Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J. and Liechtenstein, A. (1998) "In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates", Leukemia 12, 220-229.
  • Yaccoby, S., Barlogie, J. and Epsteinh, J. (1998) "Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system", Blood 92 (Suppl. 1), 106A.
  • Shipman, C.M., Vanderderken, K., Rogers, M.J., Lippitt, J.M., Asosingh, K., Hughes, D.E., Camp, B.V., Russel, G.G. and Croucher, P.I. (2000) "The potent bisphoxphonate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma". British Journal of Haematology 111, 283-286.
  • Dhodapkar, M.V., Singh, J., Mehta. J., Fassas, A., Deskan, K.R., Perlman, M., Munshi, N.C. and Barlogie. B. (1998) "Anti-myeloma activity of pamidronate in vivo", British Journal of Haematology 103, 530-532.
  • Corso, A., Astori, C., Orlandi, E., Zappasodi, P., Arcaini. L. and Bemasconi. C. (1999) "Transient response of myeloma clone to pamidronate therapy". Haentatologica 84, 759-760.
  • Kondo. H. and Mori, A. (2002) "Anti-tumor activity of pamidronate in human multiple myeloma". Leukemia and Lymphoma 43, 919-921.
  • Martin, A., Garcia-Sanz, R., Hernandez, J., Blade. J., Suquia, B., Fernandez-Calvo, J., Gonzalez, M., Mateo, G., Orfao, A. and San Miguel, J.F. (2002) "Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect", British Journal of Haemaology 118, 239-242.
  • Durie, B.G.M. and Salomon, S.E. (1975) "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical feature, response to treatment and survival", Cancer 36, 842-854.
  • Barlogie, B., Smith, L. and Alexanian, R. (1984) "Effective treatment of advanced multiple myeloma refractory to allekylating agents", New England Journal of Medicine 310, 1353-1356.
  • Browman, G.P., Bergsagel, D., Sicheri, D., O'Reilly, S., Wilson, K.S., Rubin, S., Belch, A., Shustik. C., Barr, R., Walker, I., James, K., Zee, B. and Johnston, D. (1995) "Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trial Group". Journal of Clinical Oncology 13, 2354-2360.
  • The Nordic Myeloma Study Group(1996) "Interferon alpha2b added to melphalan-predonine for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial", Annals of Internal Medicine 124, 212-222.
  • Salmon, S.E., Crowlcy, JJ., Grogan,T.M., Finley, P., Pugh, R.P. and Barlogie, B. (1994) "Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma", Journal of Clinical Oncology 12, 2405-2414.
  • Harousseau, J.L. (1994) "Therapeutic use of cytokines in human multiple myeloma", In: Klein. B., ed, Cytokines in Human Multiple Myeloma (R.G. Landes, Auslin. TX), pp 97-112.
  • van Zaanen, H.C., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., van der Lelie, J. and van Oers, M.H. (1998) "Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I doseescalating study", British Journal of Haematology 102, 783-790.
  • Shipiman, CM., Croucher, P.l., Russell, G.G., Helfrich, M.H. and Rogers, MJ. (1998) 'The bisphosphonate incarbonate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway", Cancer Research 58, 5294-5297.
  • Kunzman, V., Bauer, E., Feurle, J.J., Weibinger, F. Tony, H.-P. and Wilheim, M. (2000) "Stimulation of T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma". Blood 96, 384-392.
  • Das, H., Wang, L.,. Kamath, A. and Buckowski, J.F. (2001 ) "V?2d2 T-cell receptor mediated recognition of aminobisphosphates", Blood 98, 1616-1618.
  • Terpos, E., Palermos, J., Viniou, N., Valopoulos, G., Meletis, J. and Yataganas, X. (2001) "Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau under interferon-alpha treatment". Calcified Tissue lnternational 68, 285-290.
  • Yaccoby, S., Pearse, R.N., Jonson, C.L., Barlogie, B., Choi, Y. and Epstein, J. (2002) "Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity", British Journal of Haematology 116, 278-290.
  • Wisloff, F. Hjorth, M., Kassa, S. and Westin, J. (1996) "Effect of Interferon on the health-related quality of life of multiple myeloma patients: result of a Nordic randomized trial comparing melphalanpredonine to melphalan-predonine + alpha-interferon". British Journal of Haematology 124, 212-222.
  • Ali, S.M., Eslevo, F.J., Hortobagyi, G., Harvey, H., Seaman, J., Knight, R., Costa, L. and Lipton, A. (2001) "Safety and efficacy of bisphosphonates beyond 24 months in cancer patients". Journal of Clinical Oncology 19, 3434-3437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.